Lindus Health的动态

?? Join Dr. Peter Kaiser as he delves into the significant advancements in ophthalmic treatment with the introduction of Bayer | Ophthalmology 8 mg aflibercept. Discover how this higher dosage is making strides in patient care, allowing for extended treatment intervals and improved outcomes, especially for those with challenging cases. Dr. Kaiser shares his experiences and the promising results observed in two distinct patient groups, showcasing the drug's versatility and effectiveness. Tune in to gain valuable insights into this groundbreaking development in ophthalmology! #COPHY2024 #Aflibercept8mg #OphthalmologyInnovation #PatientCareProgress #OphthalmologyResearch?#PatientCare?#HealthcareEducation #retina?#OphthalmologyFuture?#medicalinnovation?#glaucoma #Surgicalretina?#uveitis?#neuropathy COPHy Congress

Long-term #Teprotumumab “offers minimal long term improvement in the management of diplopia” for patients with #ThyroidEyeDisease (TED) and, at 2 years, has a high rate of proptosis recurrence and clinical activity score (CAS) regression, according to a study published in the American Journal of Ophthalmology. Approximately two-thirds of patients did not experience a continued response after 2 years of teprotumumab treatment, according to the report. Read here: https://brnw.ch/21wH0Oh #LongTermTeprotumumab #Diplopia #TED #Proptosis #Ophthalmologist #ClinicalActivityScore #Ophthalmology #EyeCare #EyeHealth

Thanks to curated #RWD, we're gaining insights into cataracts, which are the leading cause of vision loss in the U.S. Learn how our recent partnership with the FDA and the American Academy of Ophthalmology led to major findings surrounding #IOL use among young patients with cataracts: https://hubs.la/Q02zhLTz0

An #YOs Interested in glaucoma? Here are our top tips from Real World Ophthalmology for recommendations of #MIGS. Check out our reals below and learn about the good candidates for MIGS!

Our Ophthalmology capabilites and expertise are second to none. if you have a spare minute, watch the below. AC #syneos #opthalmology

Novai is delighted that Astellas Pharma have provided external validation of DARC in a new peer reviewed publication - https://lnkd.in/dmt4Nume. The new paper published in TVST (Association for Research in Vision and Ophthalmology (ARVO)) reveals that?'DARC technology can effectively assess glaucomatous damage' in the most translatable model of OHT that exists, and shows increases in DARC with elevated IOP. Most importantly, a 'statistically significant relationship between cumulative DARC counts and reductions in Retinal Nerve Fibre Layer (RNFL) thickness on OCT both globally and in each peripapillary sector' was established. #Novai #Glaucoma #OHT #DARC #astellas #endpoints #clinicaltrials #biomarker #earlydetection #innovation #opthalmology #amd #retina #degeneration #artificialintelligence #lifesciences #innovation

Patients with neovascular #AgeRelatedMacularDegeneration (nAMD) undergoing treat-and-extend #Faricimab therapy can maintain vision gains through 2 years, according to investigators of 2 global phase 3 clinical trials published in Ophthalmology (American Academy of Ophthalmology). Approximately 80% of participants who were managed faricimab reached 12 week dosing or longer. This is significant as treat-and-extend-based personalized treatment interval (T&E-based PTI) most closely mirrors real-world practice, according to the report. Read more: https://brnw.ch/21wItuu #NeovascularAgedRelatedMacularDegeneration #nAMD #Faricimab #ClinicalTrials #Ophthalmology #EyeHealth #EyeCare #Ophthalmology

Anterior uveitis and severe keratoconjunctivitis sicca in a patient with steroid-induced ocular hypertension - Case Report Fidan A. Aghayeva, MD Ines Lanzl, MD Professor (Germany) Ophthalmology Cases & Hypotheses,2024; 5(1):21-25 https://lnkd.in/ezmwBtUS

?? Geographic atrophy (GA) is one of the characteristics of advanced age-related macular degeneration (AMD) and can cause vision loss, even legal blindness. Yet, treatment options for GA or its progression remain limited. This NEI research investigated minocycline's potential to slow vision loss and halt GA expansion in AMD patients. Our VeriSee AMD, a TFDA-approved medical AI, makes early screening for AMD and early access to ophthalmic care possible. Together, we can improve public health of eye care! #AMD #GeographicAtrophy #EyeHealth #NEI #AcerMedical #VeriSeeAMD

Here are some insights on Bromfenac, a powerful nonsteroidal anti-inflammatory drug (NSAID) that has revolutionized pain management in ophthalmology. ?? ?? Swipe Right to Learn More! ?? Or Contact us! ?? https://lnkd.in/encYiXcZ #painmanagement #ophthalmology #bromfenac #postcataractsurgery